Stephens analyst Sudan Loganathan initiated coverage of Immunome (IMNM) with an Overweight rating and $30 price target as the firm is adding to its biotechnology research coverage with a focus on antibody-drug delivery technologies for the treatment of cancers. Immunome has a late stage asset in AL102 for desmoid tumors, as well as a “strong cash position and seasoned leadership in ADC technology,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM: